VYGR Voyager Therapeutics, Inc.
Price Chart
Executive Summary
Voyager Therapeutics announced FDA clearance of its IND application for VY1706, a tau silencing gene therapy for Alzheimer's disease. The company plans a Phase 1 open-label dose-escalation trial in up to 18 patients with early Alzheimer's, with dosing expected to begin in H2 2026. This is a positive regulatory milestone for the pipeline, but the program remains early-stage with no financial data disclosed.
Actionable Insight
Monitor for initiation of patient dosing and any early safety or biomarker readouts, which could provide further validation of VY1706's therapeutic potential. The small trial size (18 patients) limits near-term binary risk, but positive data could significantly de-risk the program.
Key Facts
- FDA cleared IND for VY1706, a tau silencing gene therapy for Alzheimer's disease
- Phase 1 trial is open-label, dose-escalation, enrolling up to 18 patients with early Alzheimer's and tau pathology confirmed by PET
- Dosing expected to begin in the second half of 2026
- Primary endpoint is safety and tolerability; secondary endpoints include CSF tau biomarkers and tau PET imaging
- Highest dose not exceeding 5 x 10^13 vector genomes per kilogram
Financial Impact
No financial figures disclosed; preclinical-stage catalyst with no immediate revenue impact
Risk Factors
- Clinical trial failure due to safety or lack of efficacy
- Slow enrollment or delays in trial initiation
- Competition from other Alzheimer's therapies targeting tau or amyloid
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-068591 |
| Document: 0001104659-26-068591-index-headers.html | 0001104659-26-068591 |
| Document: 0001104659-26-068591-index.html | 0001104659-26-068591 |
| Document: 0001104659-26-068591.txt | 0001104659-26-068591 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 1, 2026
4d ago
|
8-K
| $3.79 $3.59 | ▼ −5.28% | ▼ −5.42% | $3.34 (−12.01%) |
|
May 16, 2026
20d ago
|
ANALYST-UPGRADE
| $5.45 $5.28 | ▼ −3.12% | ▼ −3.29% | $3.34 (−38.81%) |
|
May 13, 2026
23d ago
|
Press Release
| $4.15 $4.24 | ▲ +2.17% | ▲ +1.39% | $3.34 (−19.64%) |
|
May 7, 2026
28d ago
|
Press Release
| $4.05 $4.12 | ▲ +1.73% | ▲ +1.50% | $3.34 (−17.65%) |
|
Apr 27, 2026
5w ago
|
Press Release
| $3.77 $3.70 | ▼ −1.95% | ▼ −1.94% | $3.34 (−11.54%) |
|
Apr 21, 2026
6w ago
|
8-K
| $4.14 $4.04 | ▼ −2.42% | ▼ −2.02% | $3.34 (−19.44%) |
|
Apr 16, 2026
7w ago
|
ANALYST-UPGRADE
| $3.96 $4.13 | ▲ +4.29% | ▲ +3.08% | $3.34 (−15.78%) |
|
Apr 16, 2026
7w ago
|
ANALYST-UPGRADE
| $3.96 $4.13 | ▲ +4.29% | ▲ +3.08% | $3.34 (−15.78%) |
|
Apr 16, 2026
7w ago
|
ANALYST-UPGRADE
| $3.96 $4.13 | ▲ +4.29% | ▲ +3.08% | $3.34 (−15.78%) |
|
Feb 24, 2026
14w ago
|
Insider Cluster
| $3.78 $4.09 | ▼ −8.20% | ▼ −7.37% | $3.34 (+11.77%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access